logo-loader
viewLexagene Hldgs Inc.

LexaGene files additional US patents to protect proprietary LX2 genetic analyzer technology

The Massachusetts-based biotech is pioneering the first fully automated pathogen detection platform for use in diagnostics and sample analysis via its LX Analyzer

DNA
The genetic analyzer allows users to customize the instrument to target any pathogen of interest

LexaGene Holdings Inc (CVE:LXG) (OTCMKTS:LXXGF) announced Wednesday that it has filed additional patents to protect its proprietary LX2 genetic analyzer technology.

The company said the three US patent applications seek to provide continuing and additional coverage of its LX2 technology: the unique sample prep DNA extraction method, the data and image processing algorithms, and the fast DNA-analysis function of the instrument and system.

LexaGene, based in Beverly, Massachusetts, is pioneering the first fully automated pathogen detection platform for use in diagnostics and sample analysis via its LX Analyzer.

READ: LexaGene’s LX Analyzer exceeds expectations during testing at major veterinary hospital

The key feature is the open access nature of the genetic analyzer that allows end users to customize the instrument to target any pathogen of interest. The instrument is able to process multiple samples at a time, returning results within around one hour.

“Protecting our technology is critical for building value in the company,” said CEO Dr Jack Regan.

“These patent applications further defend our LX technology as being the first sample-to-answer microfluidic genetic analyzer that utilizes disposable cartridges and bulk fluid reservoirs for rapid and cost-efficient PCR (polymerase chain reaction) that can screen for many genetic targets at once.”

LexaGene's stock recently traded up 2.9% to C$0.70 a share in Toronto and rose 1.9% to US$0.54 in New York.

-- Updates stock price --

Contact the author: [email protected]

Follow him on Twitter @PatrickMGraham

Quick facts: Lexagene Hldgs Inc.

Price: 0.68 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $58.25 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Hldgs Inc. named herein, including the promotion by the Company of Lexagene Hldgs Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

LexaGene Holdings tackles rapid pathogen detection

LexaGene Holdings (CVE:LXG) President Daryl Rebeck tells Proactive Investors about how the biotech company continues to develop and commercialize pathogen detection devices in the biochemical industry. Rebeck says pathogens are anything that can make us ill, such as salmonella, E. coli,...

on 8/6/18

2 min read